Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

NEW YORK — Armed with hundreds of thousands of dollars from Newman's Own Foundation and Ozempic creator Novo Nordisk, young Native Americans are leading the fight against persistently high rates of ...

Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Bagsværd, Denmark and Seattle, US, 15 October 2025 -- Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Novo Nordisk said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros for up to $2.1 billion. Under the asset purchase ...

Novo Nordisk has fallen behind its archrival, Eli Lilly, in the obesity drug market. Compounded GLP-1 drugs have become such an issue that Novo Nordisk changed its CEO. Expectations are so low that ...

Omeros signs an up to $2.1 billion licensing deal with Novo Nordisk. Here's why the NVO agreeement is constructive for OMER stock. Omeros shares still remain a speculative bet at best in 2025. Omeros ...